Cargando…
Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis
In the last years, the understanding of the pathologic mechanisms of asthma and atopic dermatitis, both characterized by allergic inflammation, has greatly improved. However, it is evident that both diseases present with high heterogeneity, which complicates the diagnosis and the therapeutic approac...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514744/ https://www.ncbi.nlm.nih.gov/pubmed/34658882 http://dx.doi.org/10.3389/fphar.2021.747364 |
_version_ | 1784583460536451072 |
---|---|
author | Puzzovio, Pier Giorgio Levi-Schaffer, Francesca |
author_facet | Puzzovio, Pier Giorgio Levi-Schaffer, Francesca |
author_sort | Puzzovio, Pier Giorgio |
collection | PubMed |
description | In the last years, the understanding of the pathologic mechanisms of asthma and atopic dermatitis, both characterized by allergic inflammation, has greatly improved. However, it is evident that both diseases present with high heterogeneity, which complicates the diagnosis and the therapeutic approach of the patients. Moreover, some of the currently available strategies to treat asthma and atopic dermatitis are still mostly controlling the symptoms, but not to lead towards full healing, thus having these two diseases labelled as unmet clinical needs by WHO. Therefore, the “one-size-fits-all” strategy is outdated for asthma and atopic dermatitis, and there is the need of better methods to clearly diagnose the disease and tailor the therapy according to the specific symptomatology. In this regard, the use of biomarkers has been advanced in order to characterize both diseases according to their clinical signs and to facilitate the subsequent treatment. Despite the advancements made in this regard, there is still need for better and more sensitive biomarkers and for less invasive sampling methodologies, with the aim to diagnose specifically each manifestation of asthma and atopic dermatitis and to provide the best treatment with the least suffering for the patients. |
format | Online Article Text |
id | pubmed-8514744 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85147442021-10-15 Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis Puzzovio, Pier Giorgio Levi-Schaffer, Francesca Front Pharmacol Pharmacology In the last years, the understanding of the pathologic mechanisms of asthma and atopic dermatitis, both characterized by allergic inflammation, has greatly improved. However, it is evident that both diseases present with high heterogeneity, which complicates the diagnosis and the therapeutic approach of the patients. Moreover, some of the currently available strategies to treat asthma and atopic dermatitis are still mostly controlling the symptoms, but not to lead towards full healing, thus having these two diseases labelled as unmet clinical needs by WHO. Therefore, the “one-size-fits-all” strategy is outdated for asthma and atopic dermatitis, and there is the need of better methods to clearly diagnose the disease and tailor the therapy according to the specific symptomatology. In this regard, the use of biomarkers has been advanced in order to characterize both diseases according to their clinical signs and to facilitate the subsequent treatment. Despite the advancements made in this regard, there is still need for better and more sensitive biomarkers and for less invasive sampling methodologies, with the aim to diagnose specifically each manifestation of asthma and atopic dermatitis and to provide the best treatment with the least suffering for the patients. Frontiers Media S.A. 2021-09-30 /pmc/articles/PMC8514744/ /pubmed/34658882 http://dx.doi.org/10.3389/fphar.2021.747364 Text en Copyright © 2021 Puzzovio and Levi-Schaffer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Puzzovio, Pier Giorgio Levi-Schaffer, Francesca Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis |
title | Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis |
title_full | Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis |
title_fullStr | Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis |
title_full_unstemmed | Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis |
title_short | Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis |
title_sort | latest progresses in allergic diseases biomarkers: asthma and atopic dermatitis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514744/ https://www.ncbi.nlm.nih.gov/pubmed/34658882 http://dx.doi.org/10.3389/fphar.2021.747364 |
work_keys_str_mv | AT puzzoviopiergiorgio latestprogressesinallergicdiseasesbiomarkersasthmaandatopicdermatitis AT levischafferfrancesca latestprogressesinallergicdiseasesbiomarkersasthmaandatopicdermatitis |